 Connection
David Riches to Proto-Oncogene Proteins c-bcl-2
This is a "connection" page, showing publications David Riches has written about Proto-Oncogene Proteins c-bcl-2.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.269 |
|
|
|
-
Redente EF, Song T, Javkhlan N, Edelman BL, Foster DG, Wilson JA, Chakraborty S, Cooley JC, Gaurav R, Saguthi S, Seibold MA, Blumhagen RZ, Schwartz DA, Yang IV, Matsuda J, Bridges JP, Zemans RL, Tuder RM, Riches DWH. Conditional BCL-2 Expression in Fibroblasts Promotes Persistent Pulmonary Fibrosis which is Reversible by Therapeutic BCL-2 Inhibition. Nat Commun. 2026 Feb 28; 17(1).
Score: 0.855
-
Cooley JC, Penick SK, Wilson JA, Javkhlan N, Foster DG, Edelman BL, Schott CA, Humphries SM, Lynch DA, Schwartz DA, Riches DWH, Redente EF. Nintedanib increases BCL-2 in fibrotic fibroblasts, enhancing ABT-199 apoptosis and fibrosis resolution. Am J Respir Cell Mol Biol. 2026 Aug 01; 74(8):1103-1113.
Score: 0.220
-
Cottin V, Van Linden AA, Riches DW. Phosphorylation of the tumor necrosis factor receptor CD120a (p55) recruits Bcl-2 and protects against apoptosis. J Biol Chem. 2001 May 18; 276(20):17252-60.
Score: 0.150
-
Cooley JC, Javkhlan N, Wilson JA, Foster DG, Edelman BL, Ortiz LA, Schwartz DA, Riches DW, Redente EF. Inhibition of antiapoptotic BCL-2 proteins with ABT-263 induces fibroblast apoptosis, reversing persistent pulmonary fibrosis. JCI Insight. 2023 02 08; 8(3).
Score: 0.043
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|